AKT1 and cardiac hypertrophy: Furthermore, the results of the present study provide convincing evidence to support the concept that TRIM32 limits the development of cardiac hypertrophy, fibrosis and subsequent heart failure by interruption of the Akt-dependent signalling pathway.